Intervention not reported
Overall mean speed reduction of about 2‐3km/h seen at both experimental and control sites. Distance halo of up to 14km downstream was seen. Time halo for at least the day after enforcement.
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
A net reduction of 71.3 % (p = 0.064) in injury crashes up to and including 4 days after the presence of enforcement. A net reduction of 73.9% (p =0.045) on the day when a mix of overt/covert enforcement employed.
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
A 25% reduction in expected crash rate, 11% reduction in injury crashes and a 17% reduction in daytime crash fatalities.
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
About 25% reduction in crashes to that expected. A significant 11% reduction in number of victims, with an average decrease of 139 daytime traffic crashes requiring an ambulance. A 17% reduction in daytime crash fatalities.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hot flush frequency (number/day) · patients with hot flushes in women with a history of breast cancer
1 finding from 1 review
Hot flush frequency (number/day) · patients with hot flushes in women with a history of breast cancer
1 finding from 1 review
AW symptoms (CIWA‐Ar score) · people with alcohol withdrawal
1 finding from 1 review
AW symptoms (CIWA‐Ar score) · people with alcohol withdrawal
1 finding from 1 review
AW symptoms (CIWA‐Ar score) · people with alcohol withdrawal
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) led to lower time to heal mucositis (days) compared with antimycotic mouthrinse; GRADE not reported.
1 finding from 1 review
Time to symptom resolution · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
1 finding from 1 review
Duration of pain control therapy (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) led to lower duration of pain control therapy (days) compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to lower time to heal mucositis (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) led to lower time to heal mucositis (days) compared with povidone iodine; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Costs (fixation materials, hospital bed days, retreatment) · Adults over 18 years of age with fractures of the facial skeleton including the mandible, maxilla, zygoma (malar); studies on fractures of…
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Adverse events (day 7 to day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Intervention not reported
Pain subsequent to donation ("after collection" ‐ day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review